SCHEDULE: RA Capital Increases Artiva Bio stake to 37.9%

RA Capital Management and its affiliates have disclosed an increased beneficial ownership stake in Artiva Biotherapeutics, Inc. to 37.9% through recent open market purchases.

Summary

• RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons"), have filed an amendment to their Schedule 13D, reporting an increased beneficial ownership in Artiva Biotherapeutics, Inc.
• The Reporting Persons now collectively beneficially own 18,415,956 shares of common stock, representing approximately 37.9% of the outstanding shares.
• This increase is due to various open market purchases of common stock made by the RA Capital Healthcare Fund, L.P. between June 16, 2026, and July 23, 2026.
• The filing also notes the existence of pre-funded warrants held by the Fund, which are currently restricted from exercise due to a beneficial ownership blocker provision.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting increased conviction and investment from a significant institutional player, although the presence of unexercisable warrants tempers the immediate upside.

Positives

• RA Capital has significantly increased its investment in Artiva Biotherapeutics, indicating strong conviction in the company's prospects.
• The aggregate beneficial ownership of 37.9% suggests a substantial commitment and potential for continued influence.
• Recent open market purchases demonstrate active engagement and confidence in the current stock valuation.

Negatives

• The pre-funded warrants held by the Fund are currently unable to be exercised due to a beneficial ownership blocker, limiting immediate potential share acquisition.
• The filing is an amendment to a previous filing, indicating ongoing changes in ownership rather than a single, definitive event.

Risks

• The beneficial ownership blocker on the pre-funded warrants could prevent further exercise and ownership increase under certain conditions.
• Concentration of ownership by a single entity (RA Capital) could lead to potential governance concerns or influence over strategic decisions.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company itself. However, RA Capital's continued purchases suggest a positive outlook on the company's future performance from their perspective.

Industry Context

StockSavvy.ai notes that significant stake increases by institutional investors like RA Capital in biotechnology companies are common, often signaling confidence in the company's pipeline or strategic direction. This filing reflects active portfolio management within the competitive biotech investment landscape.

Stakeholder Impact

• Shareholders may view RA Capital's increased stake as a positive signal of confidence, potentially influencing share price.
• Management and the Board of Directors will be aware of the significant ownership concentration and potential influence of RA Capital.

Next Steps

• RA Capital will continue to monitor its beneficial ownership levels to ensure compliance with the beneficial ownership blocker provisions.
• Further open market purchases or sales by RA Capital could occur, potentially altering their ownership stake.

Key Dates

Recommendation

The filing indicates increased investment from a significant institutional holder, suggesting confidence. However, it is an amendment to an existing filing and does not contain new operational or financial results. The presence of unexercisable warrants also adds a layer of complexity. Therefore, a 'hold' recommendation is appropriate pending further company-specific developments.

Keywords

Artiva Biotherapeutics, RA Capital Management, Schedule 13D, Beneficial Ownership, Stock Purchase, Healthcare Fund, Investment Management, Warrants